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Abstract
The stimulation of 5-HT1A receptors in the raphe or their blockade in the hippocampus can reduce cognitive deficits induced by blockade
of muscarinic receptors in the hippocampus. We investigated the effects of MDL 73005 (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl-
methylamino) ethyl]-8-azaspiro[4,5] decane-7,9-dione methyl sulphonate), an agonist at 5-HT1A somatodendritic autoreceptors and an
antagonist at postsynaptic 5-HT1A receptors in rats treated systemically with scopolamine. Spatial memory was assessed in a water maze
using protocols testing reference and working memory. Home cage locomotor activity was also determined. Working memory and locomotor
activity were evaluated before and after para-chlorophenylalanine (pCPA) treatment. Scopolamine produced a weak impairment of reference
memory at 0.5 mg/kg, and a more pronounced impairment of working memory at 0.25 and 0.5 mg/kg. MDL 73005 alone (2 mg/kg, ip) had
no effect, but prevented the memory impairments induced by 0.25 mg/kg of scopolamine. Scopolamine induced hyperlocomotion. MDL
73005 alone did not affect locomotor activity, but exacerbated the hyperlocomotion induced by 0.5 mg/kg of scopolamine. pCPA did not
abolish the effects of MDL 73005, suggesting that these effects were not due to an action at presynaptic receptors, or even that they involved
receptors other than serotonergic ones (e.g., D2). In conclusion, MDL 73005 is able to antagonise moderate spatial memory dysfunctions
induced by systemic muscarinic blockade. D 2001 Elsevier Science Inc. All rights reserved.
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1. Introduction
The serotonergic system takes part in cognitive processes,
partly through an interaction with cholinergic mechanisms
(e.g., Cassel and Jeltsch, 1995; Steckler and Sahgal, 1995).
Among the different serotonergic receptors involved in cogni-
tion (Buhot,1997;Meneses,1999),5-HT1A receptorsmightbe
implicated in spatial learning and memory. For instance,
systemic treatment with the specific 5-HT1A agonist, 8-
hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), impairs
performances in various spatial learning/memory tasks (water
maze: Carli and Samanin, 1992; Carli et al., 1995a; Kant et al.,
1996, 1998; radial maze: Winter and Petti, 1987; Helsley et al.,
1998). Conversely, systemic treatment with WAY 100635
(N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyri-
dinyl-cyclohexanecarboxamide) or 100135 (N-tert-butyl-3-
(4-[2-methoxyphenyl)-1-piperazinyl)-2-phenylpropamide),
two specific 5-HT1A antagonists, prevents the impairment of
water-maze performances caused by blockade of hippocam-
pal muscarinic (Carli et al., 1995b, 1997) or N-methyl-D-
aspartate (NMDA) (Carli et al., 1999) receptors.
Regarding their anatomical distribution and functional
characteristics (e.g., Barnes and Sharp, 1999), 5-HT1A
receptors that are somatodendritic can be divided into
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two main groups. One comprises the receptors present in
the midbrain raphe nuclei (Pazos and Palacios, 1985;
Chalmers and Watson, 1991). They are considered to
operate mainly as presynaptic autoreceptors: their activa-
tion inhibits both raphe serotonergic cell firing (Sprouse,
1991; Millan et al., 1993) and serotonin (5-HT) release in
projection areas (Hjorth and Magnusson, 1988; Hutson et
al., 1989). The other group comprises heteroreceptors, i.e.,
present on neurons that are not serotonergic, found in
projection areas of the raphe nuclei, including structures
such as the hippocampus and the septal region (Pazos and
Palacios, 1985; Chalmers and Watson, 1991). There, as in
other brain regions, these receptors are considered post-
synaptic modulatory receptors (e.g., Buhot, 1997; Barnes
and Sharp, 1999).
Interestingly, the effects on spatial memory of treatments
with 5-HT1A ligands seem to depend on which of both types
of receptors is concerned. Indeed, spatial memory impair-
ments induced by systemic treatment with 8-OH-DPAT
persist in 5-HT-depleted rats (Carli and Samanin, 1992)
and are antagonised by intrahippocampal delivery of WAY
100135 (Carli et al., 1995b), suggesting an involvement of
postsynaptic 5HT1A receptors. Also, when infused into the
hippocampus (Carli et al., 1992) or the septal region
(Bertrand et al., 2000), 8-OH-DPAT impairs water-maze
performances. Conversely, when infused into the dorsal
raphe, it reverses the spatial learning impairment caused
by intrahippocampal scopolamine (Carli et al., 1998). These
data suggest that stimulation of presynaptic or blockade of
postsynaptic 5-HT1A receptors has beneficial effects on
spatial memory impairments. The 5-HT1A ligand, MDL
73005 (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl-methyla-
mino) ethyl]-8-azaspiro[4,5] decane-7,9-dione methyl sul-
phonate), has been characterised as having agonist
properties at 5-HT1A autoreceptors (termed presynaptic
hereafter) in the raphe nuclei, and antagonist properties at
postsynaptic receptors. Indeed, this compound, like 8-OH-
DPAT (a specific and well-characterised 5-HT1A agonist),
induces presynaptic 5-HT1A receptor-mediated effects, such
as inhibition of dorsal raphe cell firing (Sprouse, 1991;
Millan et al., 1993; Gobert et al., 1995) and of 5-HT release
in the hippocampus (Gartside et al., 1990). Simultaneously,
it antagonises postsynaptic 5-HT1A receptor-mediated
responses elicited by 8-OH-DPAT, such as spontaneous tail
flicks, flat body posture, decrease of body temperature
(Moser et al., 1990; Millan et al., 1993), or increase of
ACTH secretion (Gartside et al., 1990). Moreover, MDL
73005 may act as an antagonist at 5-HT1A receptors on
hippocampal CA1 pyramidal neurons (Van den Hooff and
Galvan, 1991).
The present experiment investigated the effects of sys-
temic treatment with MDL 73005 on spatial learning/mem-
ory deficits induced by muscarinic blockade. The dose of
MDL 73005 chosen was 2 mg/kg ip, as it was close to the
ID50 of 8-OH-DPAT-induced responses (about 1.5 mg/kg;
Millan et al., 1993). Spatial learning and memory were
tested using a water maze, first according to a reference
memory protocol, second according to a ‘‘working mem-
ory’’ protocol, the latter involving two spatial memory
components operating almost concomitantly, i.e., allocentric
orientation and egocentric navigation. The capabilities in the
‘‘working memory’’ protocol were evaluated before and
after inhibition of 5-HT synthesis by para-chlorophenylala-
nine (pCPA) injections in order to assess the relative
implication of pre- vs. postsynaptic 5-HT1A receptors in
the effects of MDL 73005. The effects of the drugs were
additionally assessed on locomotor activity.
2. Materials and methods
2.1. Animals
All procedures involving animals and their care were
conducted in conformity with the institutional guidelines
that are in compliance with national (Council Directive
87848, October 19, 1987, Ministe`re de l’Agriculture et de
la Foreˆt, Service Ve´te´rinaire de la Sante´ et de la Protection
Animales; permissions 6212 to J.-C.C. and 67-14bis to H.J.,
O.L., R.G., C.L., and F.B. under the former’s responsibility)
and international (NIH Publication no. 86-23, revised 1985)
laws and policies.
The study used 89 3-month-old Long–Evans male rats
(CERJ, France). The rats were housed in individual,
transparent Makrolon cages (42 26 15 cm3). Food
and water were available ad libitum. The colony and
testing rooms were maintained in a 12:12 h light–dark
cycle (lights on at 7:00 a.m.) under controlled temperature
(22°C). The rats were randomly allocated to one of eight
groups, abbreviated CTRL, CTRL + pCPA, MDL, MSCO,
SCO1, SCO2, MDL + SCO1, and MDL + SCO2 hereafter
(see below for details).
2.2. Behavioral testing
2.2.1. Timing of the experiment
The experiment started on Day 1. Spatial reference
memory was assessed from Days 1 to 5. Locomotor
activity was then measured the first time on Day 6
(Session 1). Spatial working memory was assessed from
Days 8 to 11 (Session 1). After 1 day of rest, the rats were
injected with pCPA on Days 13–15. Spatial working
memory was again assessed from Days 16 to 19 (Session
2). Locomotor activity was finally measured on Day 21
(Session 2), and all rats were sacrificed on Day 22 or 23
for neurochemical determinations.
2.2.2. Spatial memory
Spatial reference memory and spatial working memory
were assessed in a Morris water maze. The apparatus
consisted of a large circular pool (; 160 cm), half-filled
with water (temperature 20°C) made opaque with powdered
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milk. A circular platform (; 11 cm), made of transparent
plastic, was lowered 1 cm underneath the surface of the
water; it was invisible for the rat. In each trial, the rat was
placed at the edge of the pool, facing the wall, and, by using
extra-maze visual cues, had to find the platform to escape
from the water. For both reference and working memory
procedures, the rats underwent four trials on each testing
day. Each trial lasted a maximum of 60 s, after which the rat
that did not find the platform was placed on it by the
experimenter. Between two consecutive trials, the rats were
allowed to stay for 15 s on the platform. With the help of a
computerised video tracking system (Noldus, the Nether-
lands), escape latencies and distances swam between the
starting point and the platform were recorded. Rats from the
different experimental groups were tested according to a
random order that was repeated on each day of testing.
In the reference memory procedure, the rats had to
translate into memory the stable information present through
all trials. Reference-memory testing lasted for five conse-
cutive days. During the 19 first acquisition trials, the plat-
form remained at the same place (Fig. 1a), and the rats
started each time from a different starting point (Day 1: N–
E–S–W; Day 2: SE–N–SW–SE; Day 3: SW–NE–W–E;
Day 4: W–E–S–N; Day 5: NE–SW–N). For the 20th trial
(last trial of Day 5, i.e., probe trial), the platform was
removed and the rat was released from S. Time spent and
distance swam within each quadrant of the pool (Q1, Q2,
Q3, Q4, with Q3 being the probe quadrant, i.e., where the
platform was located during acquisition trials; see Fig. 1)
were determined.
In the ‘‘working memory’’ procedure, the rats had to
translate into memory new incoming information that
needed to be remembered for a specific testing day during
a short period, and that became irrelevant on the next day.
Working memory testing lasted for four consecutive days,
with four consecutive trials given each day. On each day,
the configuration of the water maze (starting point and
platform positions) remained constant, but changed from
one day to the next (Fig. 1b–e). From the first to the fourth
day of testing, the configuration of the water maze was b–
c–d–e (see Fig. 1) for the first session (Days 8–11), and
e–d–b–c (see Fig. 1) for the second session (Days 16–19)
run after pCPA treatment. As, on one specific day, the
starting point and the goal remained the same through all
daily trials, the performances of the rats with this protocol
may reflect two components of spatial memory: the allo-
centric spatial working memory, mainly through the differ-
ences of the scores between the first and the second trials,
but also possibly nonspatial strategies to search for the
platform and egocentric spatial orientation.
2.2.3. Locomotor activity
Spontaneous locomotor activity was recorded in the
home cages in a testing room with the same light and
temperature conditions as the colony room. Each cage was
traversed by two infrared light beams targeted on two
reflectors, 4.5 cm above the floor level and 28 cm apart.
The number of displacements from one extremity of the
cage to the other, defined as successive interruptions of the
infrared light beams, was monitored by a computer. The rats
were placed in the testing room 16 h before injection of the
drugs and recording in order to habituate to the room
conditions. Activity recording lasted for 6 h, from 11:00
a.m. to 5:00 p.m.
2.3. Drug treatments
CTRL (n = 9) and CTRL + pCPA (n = 12) rats were
injected with saline (NaCl 0.9%). MDL rats (n = 12) were
injected with MDL 73005 (2 mg/kg). MSCO rats (n = 12)
were injected with scopolamine methylbromide (MBr, 0.5
mg/kg), a derivative of scopolamine that poorly crosses the
blood–brain barrier and has essentially peripheral effects.
SCO1 rats (n = 11) were injected with scopolamine hydro-
bromide (HBr, centrally active) at a low dose (0.25 mg/kg).
MDL + SCO1 rats (n = 9) received both scopolamine HBr at
a low dose (0.25 mg/kg) and MDL 73005 (2 mg/kg). SCO2
rats (n = 12) were injected with scopolamine HBr at a high
dose (0.5 mg/kg). MDL + SCO2 rats (n = 12) received both
scopolamine HBr at a high dose (0.5 mg/kg) and MDL
73005 (2 mg/kg).
The drug solutions were prepared freshly on each day in
saline. Injections were performed intraperitoneally. The
animals treated with no or only one drug (i.e., CTRL,
CTRL + pCPA, MSCO, MDL, SCO1, and SCO2) received
Fig. 1. Schematic representation of the water maze and the position of the
platform (filled circle) and the virtual separation lines delimiting the four
quadrants (Q1, Q2, Q3, Q4) in the testing protocols used to assess reference
memory over 5 days [(a) same platform position each day] or working
memory over 4 days [(b)– (e) platform position and start point changed
each day]. For patterns (b)– (e), the place where the rat was released is
indicated by the arrowhead. Pre-pCPA working memory testing was made
using sequence ‘‘b–c– d –e,’’ while post-pCPA testing used sequence
‘‘e– d –b – c’’ for the placement of the platform and the release points.
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a saline injection in place of the additional drug(s). Thus, all
rats were injected at two occasions before the behavioral
evaluations. For the spatial memory procedures, on each
day, scopolamine MBr and HBr (or saline) were injected 30
min, and MDL 73005 (or saline) was injected 15 min before
the beginning of the test. For the locomotor activity mea-
surement, scopolamine MBr and HBr (or saline) were
injected 15 min, and MDL 73005 (or saline) was injected
about 2 min before recording was started.
Working memory testing was interrupted for 3 days over
which the rats were injected daily with pCPA, a tryptophane
hydroxylase inhibitor, at a dose of 500 mg/kg/day. The
pCPA was suspended in a 0.5% arabic gum solution (in
saline), prepared freshly every day. CTRL rats did not
receive pCPA, but only vehicle in order to control for
possible pCPA-induced effects.
MDL 73005 was kindly provided by Hoechst Marion
Roussel (Bridgewater, NJ, USA). All other drugs were pur-
chased from Sigma-Aldrich (St. Quentin-Fallavier, France).
2.4. Monoamine determination
One or 2 days after the last locomotor activity test, the
rats were sacrificed by microwave irradiation (2.0 s; 6.3 kW;
Sairem, Villeurbanne, France) in order to rapidly inactivate
brain enzymes (Stavinoha et al., 1973). After decapitation,
the brain was extracted and dissected on a cold plate in order
to extract the olfactory bulbs, the striatum, the frontoparietal
and occipital cortices, and the hippocampus, which was
separated into a dorsal (septal pole) and a ventral (temporal
pole) portion. The left and right structures from each rat
were pooled, weighed, and kept at ÿ 80°C until the neuro-
chemical determinations. The tissue samples were prepared
by homogenisation in 1 N formic acid/acetone (18/8.5, v/v).
Concentrations of dopamine (DA), 3,4-dihydroxyphenyla-
cetic acid (DOPAC), homovanillic acid (HVA), noradrena-
line (NA), 5-HT, and 5-hydroxyindolacetic acid (5-HIAA)
were measured using high-performance liquid chromatogra-
phy (HPLC) with electrochemical detection. The HPLC
system consisted of an ESA liquid chromatography pump
(ESA, Bedford, UK) coupled to an ESA Coulochem II
detector (ESA, Chelmsford, USA) equipped with a 5014
high-performance analytic cell (ESA, Bedford, UK). The
detector potential at the analytic cell was set at + 0.4 V. The
HPLC analysis was performed on a C18 Spherisorb ODS2
reverse-phase column (5 mm pore size, ; 4.6 mm, 25 cm
long). The mobile phase consisted of 0.1 M NaH2PO4,
pH = 3, containing 0.1 mM EDTA, 1.7 mM 1-octane sulfo-
nic acid sodium salt, and 10% acetonitrile. The flow rate
was 1 ml/min. Concentrations of the different compounds
were determined with a data analysis software (Baseline
810, Waters) and were expressed in picograms per micro-
gram of microwaved tissue.
2.5. Statistical analyses
The behavioral and neurochemical data were analysed
with a one-way analysis of variance (ANOVA) that con-
sidered the treatment factor (for swim speeds and for
monoamine concentrations) or a two- or a three-way
ANOVA that considered, in addition, one or two repeated-
measure factors (day of test for acquisition in the reference
memory procedure, quadrant for probe trial performances,
trial and session numbers for working memory procedure,
hour of observation, and session number for the locomotor
activity measurement). The ANOVA was followed, when
appropriate, by multiple two-by-two comparisons using
the Newman – Keuls test (Winer, 1971). CTRL and
CTRL + pCPA rats were considered as a single group for
analyses of reference memory performances (no pCPA
treatment was given at this stage of the experiment).
3. Results
3.1. Swim speed during the water-maze testing
Mean swim speeds during water-maze testing are shown
in Table 1. ANOVA of the swim speeds during the acquisi-
tion and probe trials of reference memory testing, and during
Table 1
Swim speeds during water-maze testing
CTRL
(n = 9)
CTRL + pCPA
(n = 12)
MSCO
(n = 12)
MDL
(n = 12)
SCO1
(n = 11)
MDL + SCO1
(n = 9)
SCO2
(n = 12)
MDL + SCO2
(n = 12)
Acquisition 26.0  0.5a 26.0  0.5 26.4  0.7 31.4  0.8*,# 31.4  0.5*,# 32.7  1.1*,# 32.2  0.8 *,#
Probe trial 28.8  0.5a 28.7  0.8 30.2  0.9 34.0  1.0*,# 33.5  1.4*,# 35.9  1.2*,# 35.6  1.2 *,#
Working memory 1 26.9  0.7 27.1  0.9 27.9  0.4 28.3  0.8 33.5  0.6*,# 32.5  0.7*,# 33.5  0.7*,# 33.2  0.6 *,#
Working memory 2 27.6  0.5# 29.7  0.6* 32.0  0.6 31.2  0.7 33.5  0.9*,# 34.2  1.1*,# 34.2  0.6*,# 34.4  0.4 *,#
Data are expressed as means  S.E.M. during the acquisition and probe trials of the reference memory testing procedure, and during the two sessions of
working memory testing procedure. Group abbreviations refer to rats that received pCPA between both working memory testing sessions and which were given
an injection of saline (CTRL + pCPA), scopolamine MBr (MSCO: 0.5 mg/kg), MDL 73005 (MDL: 2 mg/kg), scopolamine HBr (SCO1: 0.25 mg/kg; SCO2:
0.5 mg/kg), or a combination of MDL 73005 and the low (MDL + SCO1) or the high (MDL + SCO2) dose of scopolamine HBr. CTRL rats were not subjected
to pCPA treatment, but were given a saline injection before testing.
a CTRL and CTRL + pCPA rats collapsed (see Materials and Methods for detail).
* Significantly different from CTRL, P < .05.
# Significantly different from CTRL + pCPA, P < .05.
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each session of working memory testing (pre- and post-
pCPA) showed an overall effect of the treatment in all cases
[ F(7,81) = 16.64, 9.29, 19.33, and 11.44, respectively,
P < .001 in each case]. This effect was due to the fact
that rats receiving scopolamine HBr (SCO1, SCO2,
MDL + SCO1, MDL + SCO2) swam faster than CTRL and
CTRL rats to be treated with pCPA ( P < .05 in all cases). The
rats receiving scopolamine HBr swam also significantly
faster than MDL and MSCO rats during the acquisition
and probe trials of the reference memory test, as well as
during the pre-pCPA assessment of working memory
( P < .01 in each case). During the post-pCPA assessment
of working memory, the swim speed of MDL and MSCO
rats was still slower than in the rats given scopolamine HBr,
but this difference was no longer significant.
3.2. Reference memory assessment
As they were subjected to exactly the same treatment at
this stage of the experiment, CTRL and CTRL + pCPA rats
were considered a single control group for analysis and
data representation.
3.2.1. Acquisition trials
Distances and escape latencies during acquisition in
the reference memory procedure (5-day evolution and
global mean during acquisition) are shown in Figs. 2 and
3, respectively.
On the distances, ANOVA showed overall Treatment
[ F(6,82) = 8.89, P < .001] and Day [ F(4,328) = 60.35,
P < .001] effects. No significant TreatmentDay interaction
was found [ F(24,328) = 1.23]. The Treatment effect can be
explained by the observation that SCO2 and MDL + SCO2
rats presented overall distances that were significantly longer
than in the five other groups ( P < .05 in all cases). The
differences between the mean distances of the five latter
groups were not significant. The Day effect was due to a
global improvement of performances of the rats over the 5
days of testing. Indeed, global distances decreased signifi-
cantly from day to day ( P < .01 in each case).
On escape latencies, ANOVA showed an overall Day
effect [ F(4,328) = 88.89, P < .001], but neither a signifi-
cant Treatment effect [ F(6,82) = 2.14] nor a significant
TreatmentDay interaction [ F(24,328) = 0.81]. The Day
effect was due, as for distances, to an overall decrease of
the escape latencies over the 5 days of testing ( P < .05 in
each case).
Fig. 2. Mean ( + S.E.M.) distances to reach the platform in the water-maze
test assessing reference memory capabilities. The left part of the figure
shows the mean performances on each day. The right part of the figure
illustrates the mean performances with all days collapsed (i.e., the group
effect in statistical analyses). Group abbreviations refer to rats that received
an injection of saline (CTRL), scopolamine MBr (MSCO: 0.5 mg/kg),
MDL 73005 (MDL: 2 mg/kg), scopolamine HBr (SCO1: 0.25 mg/kg;
SCO2: 0.5 mg/kg), or a combination of MDL 73005 and either the low dose
(MDL + SCO1) or the high dose (MDL + SCO2) of scopolamine HBr.
Statistical analyses, overall group effect: * significantly different from
CTRL and MSCO, P < .05.
Fig. 3. Mean ( + S.E.M.) latencies to reach the platform in the water-maze
test assessing reference memory capabilities. The left part of the figure
shows the mean performances on each day. The right part of the figure
illustrates the mean performances with all days collapsed (i.e., the group
effect in statistical analyses). Group abbreviations as in Fig. 2.
Fig. 4. Mean ( + S.E.M.) percentage of distances swam (top) and time spent
(bottom) in the four quadrants of the pool during the probe trial. Group
abbreviations as in Fig. 2. Statistical analyses, TreatmentQuadrant
interaction: * significantly different from Q3, P < .05.
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3.2.2. Probe trial
The distances swam and the time spent in each of the
four quadrants of the pool during the probe trial are shown
in Fig. 4.
Analysis was first performed on the performances in the
sole probe quadrant. On the distances swam in the probe
quadrant, ANOVA failed to show a significant Treatment
effect [ F(6,82) = 0.649, P=.69]. On the time spent in the
probe quadrant, ANOVA showed a significant Treatment
effect [ F(6,82) = 2.766, P < .05], which was due to a sig-
nificantly longer time spent by the MSCO rats in the probe
quadrant as compared to SCO2 and MDL + SCO2 rats
( P < .05 in each case).
As the groups treated with scopolamine HBr exhibited
higher swim speeds, which might reflect a sensorimotor bias
that could lead to misinterpretation of the data, analysis was
also performed on the repartition of the distances swam and
the time spent in each of the four quadrants, according to a
TreatmentQuadrant design.
On the distances swam in the different quadrants,
ANOVA showed significant Treatment [ F(6,82) = 9.68,
P < .001] and Quadrant [ F(3,246) = 53.93, P < .001] effects,
as well as a significant TreatmentQuadrant interaction
[ F(18,246) = 2.24, P < .01]. The Treatment effect reflects
the differences in the swim speed mentioned above. Indeed,
as all rats were tested during a fixed time (60 s) and as
SCO1, MDL + SCO1, SCO2, and MDL + SCO2 rats swam
faster than CTRL, MSCO, and MDL rats, those of the
former four groups swam an overall distance that was
significantly longer than that in the other three groups
( P < .05 in all cases). The Quadrant effect was due to
overall distances that were significantly longer in Quadrant
3, i.e., the probe quadrant, compared to each of the three
other quadrants ( P < .001 in all cases), as well as in
Quadrant 2 (next to the probe quadrant and the starting
point) compared to Quadrants 1 and 4 ( P < .01 in both
cases). The TreatmentQuadrant interaction can be
explained by the fact that the repartition of the distances
swam in the different quadrants was not equivalent in all
treatment groups. In particular, we noticed that CTRL and
MSCO rats swam a distance in the probe quadrant which
was significantly longer than in each of the three other ones
( P < .001 in all cases). In MDL rats, the distance swam in
the probe quadrant was significantly longer than that swam
in Quadrants 1 and 4 ( P < .05 in each case). In SCO2 and
MDL + SCO2 rats, there was no significant difference on
the distance swam in the four quadrants. Interestingly,
whereas SCO1 rats were moderately impaired (the distance
in the probe quadrant being significantly different only from
that swam in Quadrant 2, P < .01), MDL + SCO1 rats
showed a distance in the probe quadrant that was signifi-
cantly longer than that swam in each of the three other
quadrants ( P < .05 in all cases). On the time spent in the
different quadrants, ANOVA showed a significant Quadrant
effect [ F(3,246) = 56.12, P < .001] and a significant Treat-
mentQuadrant interaction [ F(18,246) = 2.64, P < .001].
The Quadrant effect was due to the fact that the time spent
in Quadrant 3, i.e., the probe quadrant, was significantly
longer than that spent in each of the three other quadrants
( P < .001 in each case), and also to the fact that the time
spent in Quadrant 2 was significantly longer than that spent
in Quadrants 1 and 4 ( P < .01 in each case). The Treat-
mentQuadrant interaction can be explained by the fact
that the repartition of the time spent in the different
quadrants was not equivalent in the seven treatment groups.
CTRL, MDL, and MSCO rats spent a significantly longer
time in the probe quadrant than in either quadrant ( P < .05
in all cases). SCO2 and MDL + SCO2 rats spent a time that
was not significantly different among the four quadrants.
Interestingly, whereas SCO1 rats were moderately impaired
(the time spent in the probe quadrant being significantly
different only from that in Quadrant 2, P < .05),
MDL + SCO1 rats showed a time spent in the probe quad-
rant which was significantly longer than in each of the other
three quadrants ( P < .05 in each case).
3.3. Working memory assessment
Distances and escape latencies (four-trial evolution and
global mean) during the two working memory sessions,
Fig. 5. Mean ( + S.E.M.) distances to reach the platform in the water-maze
test assessing working memory capabilities before (top) and after (bottom)
pCPA treatment. The left part of the figure shows the mean performances
on each trial averaged over the four testing days. The right part of the figure
illustrates the mean performances with all trials collapsed (i.e., the group
effect in statistical analyses). Group abbreviations refer to rats that had
received pCPA between both testing sessions and which were given an
injection of saline (CTRL + pCPA), scopolamine MBr (MSCO: 0.5 mg/kg),
MDL 73005 (MDL: 2 mg/kg), scopolamine HBr (SCO1: 0.25 mg/kg;
SCO2: 0.5 mg/kg), or a combination of MDL 73005 and the low
(MDL + SCO1) or the high dose (MDL + SCO2) of scopolamine HBr.
CTRL rats were not subjected to pCPA treatment, but were given a saline
injection before testing. Statistical analyses: * significantly different from
CTRL and MSCO, P < .05; + significantly different from CTRL + pCPA,
P < .05; circle with four lines, significant effect of MDL vs. SCO1, P < .05;
xsignificant effect of MDL vs. SCO2, P < .05.
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before and after pCPA treatment, are shown in Figs. 5 and
6, respectively.
On the distances, ANOVA showed significant Treatment
[ F(7,81) = 16.30, P < .001], Trial [ F(3,243) = 25.53,
P < .001], and Session [ F(1,81) = 8.18, P < .01] effects,
and also a significant Treatment Session interaction
[ F(7,81) = 2.93, P < .01]. No significant TreatmentTrial
[ F(21,243) = 1.58], Trial Session [ F(3,243) = 0.61], and
TreatmentTrial Session [ F(21,243) = 1.16] interactions
were found. The Treatment effect was due to distances swam
by CTRL, CTRL + pCPA, MDL, and MSCO rats, which
were significantly shorter than those of SCO1, SCO2, and
MDL + SCO2 rats ( P < .005 in all cases). Interestingly, in
MDL + SCO1 rats, the distances were significantly shorter
than those found in SCO1 rats ( P < .001), and did not differ
significantly from those found in control rats. The Trial effect
reflects an overall decrease of the distances over the four
trials of the test. Indeed, the distances swam on Trial 1 were
significantly longer than on the other three trials ( P < .001 in
all cases), and those on Trial 2 were significantly longer than
on the last two trials ( P < .01 in both cases). The Session
effect may be explained by the fact that overall distances
swam during the second session were greater than during the
first session. The Treatment Session interaction may be
explained by an overall increase of the distances swam by the
rats treated with scopolamine HBr during the second session
(see Fig. 5). This difference was significant for the distances
swam by SCO2 rats (Session 1 vs. Session 2, P < .01).
Consequently, whereas distances swam by MDL + SCO2
rats did not differ from those of SCO2 rats during Session
1, they were significantly shorter during Session 2 ( P < .05).
Importantly, the distances of CTRL and CTRL + pCPA rats
were not significantly different between both sessions,
suggesting that neither the treatment with pCPA nor the
repetition of the working memory procedure influenced the
performances of the rats.
Concerning escape latencies, ANOVA showed signifi-
cant Treatment [ F(7,81) = 16.30, P < .001] and Trial
[ F(3,243) = 32.64, P < .001] effects, and significant
Trial Session [ F(3,243) = 2.86, P < .05], TreatmentTrial
Trial [ F(21,243) = 3.18, P < .001], and Treatment Session
[ F(7,81) = 4.30, P < .001] interactions. There was neither a
significant Session effect [ F(1,81) = 2.86] nor a significant
TreatmentTrial Session interaction [ F(21,243) = 1.03].
The Treatment effect was due to the fact that escape
latencies of CTRL, MDL, and MSCO rats, which did not
differ from each other, were significantly shorter than those
of SCO1, SCO2, and MDL + SCO2 rats ( P < .05 in all
cases). The escape latencies of CTRL + pCPA rats were
intermediate, as they did not differ significantly from those
of CTRL rats or those of SCO1, SCO2, and MDL + SCO2
rats. Interestingly, the escape latencies of MDL + SCO1 rats
did not differ from those of CTRL rats and were signifi-
cantly shorter than those of SCO1 rats ( P < .05). The Trial
effect reflected an overall decrease of the escape latencies
over trials. Indeed, the escape latencies on Trial 1 were
significantly longer than on either trial ( P < .001 in each
case). On Trial 2, escape latencies were longer than on the
two last trials ( P < .05 in both cases). It is noteworthy that
the decrease of escape latencies over trials was more
important during Session 1 (ÿ 35%) than during Session
2 (ÿ 20%), a difference which may explain the Trial Ses-
Session interaction. The TreatmentTrial interaction may
be explained by the differences among the groups in the
improvement of the escape latencies over the four trials. For
instance, whereas the decrease of the escape latencies
between Trials 1 and 4 was quite important in CTRL,
CTRL + pCPA, MSCO, and MDL rats (ÿ 33%, ÿ 49%,
ÿ 41%, and ÿ 51%, respectively), that in SCO1, SCO2, and
MDL + SCO2 rats was much weaker (ÿ 28%, + 1%, and
ÿ 5%, respectively). It is noteworthy that the improvement
of the escape latencies of the MDL + SCO1 rats was small
(ÿ 9%), but the animals started already on Trial 1 with
small latencies. The Treatment Session interaction may
mainly reflect an important increase of the latencies of the
SCO1 and SCO2 rats during the second session (Session 1
vs. Session 2, P < .05). As a consequence, when the com-
parisons were made within each session, the beneficial
effect of MDL 73005 in MDL + SCO1 rats was confirmed
statistically only in the second session. Importantly, as for
distances, the escape latencies of CTRL and CTRL + pCPA
rats were not significantly different between both sessions,
suggesting that neither the treatment with pCPA nor the
repetition of the working memory procedure affected the
performances of the rats.
Fig. 6. Mean ( + S.E.M.) latencies to reach the platform in the water-maze
test assessing working memory capabilities before (top) and after (bottom)
pCPA treatment. The left part of the figure shows the mean performances
on each trial averaged over the four testing days. The right part of the figure
illustrates the mean performances with all trials collapsed (i.e., the group
effect in statistical analyses). Group abbreviations as in Fig. 5. Statistical
analyses: * significantly different from CTRL and MSCO, P < .05;
+ significantly different from CTRL + pCPA, P < .05; circle with four lines,
significant effect of MDL vs. SCO1, P < .05.
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Additionally, analysis was performed on distances and
escape latencies on the first and second trials, which account
more specifically for the working memory dimension of the
test. Differences between Trials 1 and 2 and global means
are shown in Figs. 7 and 8.
On the distances, ANOVA showed significant Treatment
[ F(7,81) = 10.52, P < .001], Trial [ F(1,81) = 9.26, P < .01],
and Session [ F(1,81) = 5.51, P < .05] effects, and also a
significant Treatment Session interaction [ F(7,81) = 2.86,
P < .05]. No significant TreatmentTrial [ F(7,81) = 1.34],
Trial  Session [ F(1,81) = 1.42], and Treatment  -
Trial Session [ F(7,81) = 1.06] interactions were found.
The Treatment effect was due to distances swam by CTRL,
CTRL + pCPA, MDL, MSCO, and MDL + SCO1 rats that
were significantly shorter than those of SCO1, SCO2 and
MDL + SCO2 rats ( P < .01 in all cases). The Trial effect
reflects an overall decrease of the distances between Trials 1
and 2. The Session effect may be explained by the fact that
overall distances swam during the second session were
greater than during the first session. The Treatment Ses-
Session interaction may be explained by an overall increase
of the distances swam by the rats treated with scopolamine
HBr during the second session (see Fig. 7). This difference
was significant for the distances swam by SCO2 rats
(Session 1 vs. Session 2, P < .01), and tended to reach
significance for SCO1 rats (Session 1 vs. Session 2,
Fig. 7. Mean ( + S.E.M.) differences between Trials 1 and 2 (left) and mean with the two trials collapsed (i.e., the group effect in statistical analyses, right) of
distances to reach the platform in the water-maze test assessing working memory capabilities before (top) and after (bottom) pCPA treatment. Group
abbreviations as in Fig. 5. Statistical analyses: * significantly different from CTRL; + significantly different from CTRL + pCPA, P < .05; #significantly
different from MSCO, P < .05; circle with four lines, significant effect of MDL vs. SCO1, P < .05.
Fig. 8. Mean ( + S.E.M.) differences between Trials 1 and 2 (left) and mean with the two trials collapsed (i.e., the group effect in statistical analyses; right) of
escape latencies in the water-maze test assessing working memory capabilities before (top) and after (bottom) pCPA treatment. Group abbreviations as in Fig.
5. Statistical analyses: * significantly different from CTRL; + significantly different from CTRL + pCPA, P < .05; #significantly different from MSCO, P < .05;
circle with four lines, significant effect of MDL vs. SCO1, P < .05.
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P=.056). As a consequence, the Treatment Session inter-
action may be explained by the fact that major differences
among treatments were found during Session 2. Indeed,
during Session 1, only the distances of SCO1 rats differed
significantly from those of MSCO rats ( P < .05), and the
distances of MDL + SCO2 rats were significantly different
from those of MSCO and CTRL + pCPA rats ( P < .05 in
each case). In contrast, during Session 2, SCO1 and SCO2
rats swam significantly longer distances than CTRL,
CTRL + pCPA, MSCO, and MDL rats ( P < .001 in all
cases). In addition, SCO1 rats swam a significantly longer
distance than MDL + SCO1 rats. Such an effect of MDL
73005 was not found in MDL + SCO2 rats, conversely to
what was found with the analysis performed on all four
trials (see above). Importantly, the distances of CTRL and
CTRL + pCPA rats were not significantly different between
both sessions, suggesting that neither the treatment with
pCPA nor the repetition of the working memory procedure
influenced the performances of the rats.
Concerning escape latencies, ANOVA showed signifi-
cant Treatment [ F(7,81) = 3.09, P < .001] and Trial
[ F(1,81) = 27.33, P < .001] effects, and significant
Trial Session [ F(1,81) = 4.32, P < .05], TreatmentTrial
[ F(7,81) = 2.31, P < .001], and Treatment Session
[ F(7,81) = 3.67, P < .01] interactions. There was neither a
significant Session effect [ F(1,81) = 0.41] nor a significant
TreatmentTrial Session interaction [ F(7,81) = 1.34].
The Treatment effect was due to the fact that the escape
latency of SCO1 rats was longer than those of MSCO and
MDL + SCO1 rats ( P < .05 in each case). The Trial effect
reflected an overall decrease of the escape latencies
between Trials 1 and 2. It is noteworthy that the decrease
of escape latencies between the first two trials was more
important during Session 1 (ÿ 25%) than during Session 2
(ÿ 12%), a difference which may explain the Trial Ses-
Session interaction. Therefore, global escape latencies on
the Trial 2 were significantly longer during Session 2 than
during Session 1 ( P < .05). The TreatmentTrial interac-
tion may be explained by the differences among the groups
in the improvement of the escape latencies between the
first two trials. For instance, whereas the decrease of the
escape latencies between Trials 1 and 2 was quite impor-
tant in CTRL, CTRL + pCPA, MSCO, and MDL rats
(ÿ 24%, ÿ 24%, ÿ 28%, and ÿ 41%, respectively), that
in SCO1, SCO2, and MDL + SCO2 rats was weaker
(ÿ 19%, ÿ 9%, and + 3%, respectively). It is noteworthy
that the improvement of the escape latencies of the
MDL + SCO1 rats was small (ÿ 4%), but the animals
started already on Trial 1 with small latencies. The Treat-
ment Session interaction may mainly reflect an important
increase of the latencies of the rats treated with only
scopolamine HBr during the second session in comparison
to the first. This increase was significant for SCO1 rats
(Session 1 vs. Session 2, P < .05). As a consequence, when
the comparisons were made within each session, the
beneficial effect of MDL 73005 in MDL + SCO1 rats
was confirmed statistically only in the second session.
Importantly, as for distances, the escape latencies of CTRL
and CTRL + pCPA rats were not significantly different
between both sessions, suggesting that neither the treat-
ment with pCPA nor the repetition of the working memory
procedure affected the performances of the rats.
3.4. Spontaneous locomotor activity
Mean locomotor activity scores during each session are
shown in Fig. 9.
ANOVA showed overall Treatment [ F(7,81) = 20.58,
P < .001], Hour of observation [ F(5,405) = 203.95,
P < .001], and Session [ F(1,81) = 34.26, P < .001] effects, as
well as significant Treatment Session [ F(7,81) =5.23,
P < .001], TreatmentHour [ F(35,405) = 16.74, P < .001],
Hour Session [ F(4,405) = 24.44, P < .001], and Treat-
mentHour Session [ F(35,405) = 3.46, P < .001] inter-
actions. The Treatment effect may be explained by the
differences in locomotor activity among different groups.
The lowest overall locomotor activity was found in CTRL,
CTRL + pCPA, MSCO, and MDL rats. This activity was
significantly lower than that found in SCO1, SCO2, and
MDL + SCO1 rats ( P < .01 in each case). MDL 73005
seemed to exacerbate the scopolamine HBr-induced hyper-
activity since MDL + SCO2 rats were much more active
than the rats from all other groups ( P < .001 in each case).
The Hour effect reflects an important decrease of the overall
locomotor activity over the 6 h of recording. Indeed, during
the first and second hours, the overall activity levels were
significantly higher than during the four subsequent hours
( P < .001 in all cases). The Session effect and the Treat-
ment Session interaction may be explained by an increase
Fig. 9. Mean ( + S.E.M.) locomotor activity scores before (empty bar) and
after (filled bar) pCPA treatment. Group abbreviations as in Fig. 5.
Statistical analyses, group effect: * significantly different from CTRL,
CTRL + pCPA and MSCO, P < .05; xsignificantly different from SCO1,
SCO2, MDL + SCO1, P < .05 (pre- and post-pCPA collapsed); Session
effect: #post-pCPA significantly different from pre-pCPA within the same
group, P < .05.
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of the overall activity levels after the pCPA treatment that
was essentially due to the scores of the rats treated with
scopolamine HBr. This increase was significant for SCO1,
MDL + SCO1, and MDL + SCO2 rats ( P < .05 in all cases),
and tended to reach significance for SCO2 rats ( P=.10). In
contrast, no significant change was observed after pCPA
treatment for the other groups, especially for the
CTRL + pCPA rats. Also, the activity of CTRL rats that
did not receive pCPA was not affected between both
sessions, suggesting that the repetition of recording did
not affect the spontaneous activity. The TreatmentHour,
Hour Session, and TreatmentHour Session interac-
tions may be explained by the fact that all the rats were
hyperactive in the first 2 h of observation, but the level of
this hyperactivity depended on both the treatment and the
session (see above).
Table 2
Monoamine concentrations in the different brain structures examined
CTRL
(n = 9)
CTRL + pCPA
(n = 12)
MSCO
(n = 12)
MDL
(n = 12)
SCO1
(n = 11)
MDL + SCO1
(n = 9)
SCO2
(n = 12)
MDL + SCO2
(n = 12)
Occipital cortex
5-HT 597  98 241  38* 233  42* 225  15* 192  13* 243  42* 223  14* 180  13*
5-HIAA 341  65 113  29* 131  40* 91  11* 73  8* 79  24* 66  4* 57  3*
DA 198  38y 278  50 329  34* 257  49 157  17y 151  22y 160  13y 139  6y
DOPAC 128  4 142  17 145  12 143  11 130  9 118  7 135  10 115  8
HVA 71  5 87  16 113  9 84  13 48  5y,# 46  5y,# 48  4y,# 46  3y,#
NA 370  40 319  18 283  16 314  17 301  17 324  21 304  23 289  16
Frontoparietal cortex
5-HT 765  65 195  10* 217  13* 190  12* 192  14* 240  56* 195  7* 184  14*
5-HIAA 532  53 109  8* 157  11* 116  10* 94  9* 112  27* 87  3* 91  8*
DA 980  106 901  125 1025  124 992  88 1161  148 787  71 1012  78 988  80
DOPAC 484  58 371  45 522  80 435  53 404  50 289  24 349  37 358  31
HVA 213  20 181  9 198  10 187  10 203  24 150  17 178  11 178  13
NA 506  40 447  26y 558  39# 454  31 381  26y 390  29y 369  11y 370  15y
Dorsal hippocampus
5-HT 965  60 272  25* 340  23* 290  17* 224  10* 323  90* 252  21* 223  14*
5-HIAA 1023  102 201  16* 251  20* 216  14* 174  9* 241  74* 182  13* 174  9*
DA 373  93 294  33 421  42 313  41 305  74 219  20 271  22 267  25
DOPAC 268  39 376  50 408  60 328  39 236  25y 224  23y 265  35y 218  15y
HVA 151  21y 182  25 212  22* 159  14 118  4y 113  8 y 126  9y 128  12y
NA 534  26 467  30 517  23 488  36 404  14y 451  28 403  18y 398  12y
Ventral hippocampus
5-HT 1285  112 259  28* 348  21* 280  19* 208  14* 335  123* 227  23* 211  17*
5-HIAA 1160  119 197  20* 300  22* 221  18* 156  13* 223  71* 150  10* 149  6*
DA 278  17 261  26 212  15 229  21 257  18 279  30 278  19 257  15
DOPAC 258  25 220  13 272  44 201  10 193  13 202  13 213  21 212  12
HVA 78  9 87  13 87  20 83  13 105  6 109  4 113  9 107  4
NA 845  38y,# 699  43 * ,y 826  27# 759  36 620  27y 674  39y 630  36y 640  22y
Striatum
5-HT 1207  152 366  28* 333  35* 386  35* 356  26* 474  90* 402  30* 375  22*
5-HIAA 1396  187 251  26* 285  26* 262  19* 231  16* 328  90* 244  16* 243  13*
DA 4712  363y,# 6327  322* 7364  367* 5925  471* ,y 4189  275y,# 4110  215y,# 4626  215y,# 4615  207
DOPAC 2841  185 2838  172 3263  274 2961  217 2212  265 2291  70 2247  300 2321  227
HVA 1351  95 1170  70 1381  95 1248  110 1200  98 1311  110 1223  101 1279  66
NA 363  40 405  55 384  25 413  68 324  26 345  23 374  32 449  84
Olfactory bulbs
5-HT 854  55 464  210* 548  93* 329  47* 303  49* 422  93* 338  53* 246  38*
5-HIAA 432  39 185  63* 194  31* 125  28* 121  37* 94  37* 125  23* 95  14*
DA 1110  347 750  203 509  103 337  47 775  210 484  81 1433  257y 856  209
DOPAC 592  72 543  155 371  36 401  55 489  83 361  60 554  51 451  109
HVA 282  56 183  37 148  19 189  51 187  36 156  30 235  33 267  99
NA 751  103 698  166 652  79 559  73 552  61 487  59 574  79 506  54
Data are expressed as means  S.E.M. (in picograms per microgram of microwaved tissue). Group abbreviations as in Table 1.
* Significantly different from CTRL, P < .05.
y Significantly different from MSCO, P < .05.
# Significantly different from CTRL + pCPA, P < .05.
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3.5. Monoamine determination
Mean concentrations of monoamines in the different
structures assessed are shown in Table 2. Analysis was
performed individually for each monoamine/metabolite in
each structure.
On the concentrations of serotonergic markers (5-HT and
its metabolite, 5-HIAA), a significant effect of the treatment
was found in all structures (Table 2). Indeed, whatever
structure was considered, the rats treated with pCPA
(CTRL + pCPA, MSCO, MDL, SCO1, MDL + SCO1,
SCO2, MDL + SCO2) presented a massive reduction of
serotonergic markers in comparison to the rats of the CTRL
group, which did not receive pCPA ( P < .001 in all cases; see
Table 2). This reduction reached 60–70% in the olfactory
bulbs and in the various cortical regions, and 70–80% in
both regions of the hippocampus and in the striatum.
Significant effects of the treatment were also found on
the concentrations of catecholaminergic markers in some
structures (Table 2). These effects were mainly due to a
reduction of catecholamine concentrations in the rats treated
with scopolamine HBr (SCO1, MDL + SCO1, SCO2,
MDL + SCO2) as compared to the rats that received scopo-
lamine MBr (MSCO), and, to a lesser extent, to those of the
CTRL + pCPA group ( P < .05). In the occipital cortex, DA
and HVA concentrations were significantly reduced in all
groups treated with scopolamine HBr ( P < .05). In the
frontoparietal cortex and the ventral hippocampus, NA
concentration was also significantly reduced in all these
groups ( P < .05). In the dorsal hippocampus, NA, DOPAC,
and HVA concentrations were significantly reduced in all
these groups except the MDL + SCO1 group ( P < .05).
Finally, in the striatum, DA concentration was significantly
reduced in all groups treated with scopolamine HBr, as well
as in the MDL and CTRL groups ( P < .05).
4. Discussion
The present experiment assessed the effects of MDL
73005 given systemically on Morris water-maze perfor-
mances and on locomotor activity in rats pretreated with
scopolamine. As compared to scopolamine MBr or saline,
the centrally active scopolamine (1) weakly but significantly
impaired reference memory; (2) impaired working memory
more markedly; and (3) induced locomotor hyperactivity in
the home cage. MDL 73005 had no effect by itself, but
reduced the moderate impairment elicited by the low dose of
scopolamine in the water-maze tasks and potentiated the
locomotor effect of the high dose of scopolamine. These
effects were still present, in some respect even exacerbated,
after pCPA treatment.
The treatment with pCPA produced an important, though
not complete, 5-HT depletion, as indicated by a 60–80%
reduction of 5-HT and 5-HIAA concentrations in all brain
structures examined. This observation suggests that the
beneficial effects of MDL 73005 were not due to an action
of the compound at only the presynaptic 5-HT1A receptors,
which, when stimulated, decrease the 5-HT tone in projec-
tion areas, an effect also induced by pCPA. On the one hand,
if the effect of MDL 73005 on the scopolamine-induced
deficits was due to an action as an agonist at presynaptic 5-
HT1A receptors, pCPA should have produced an effect
similar to the one induced by MDL 73005, and perhaps
should have potentiated the latter. If so, any other 5-HT
receptor, but the 5-HT1A subtype, might be involved at the
postsynaptic level. Our data show that pCPA did not mimic
the effects of MDL 73005; pCPA even exacerbated some of
the behavioral effects of scopolamine. If, on the other hand,
the effect of MDL 73005 on the deficits produced by
scopolamine was due to an action as an antagonist at
postsynaptic 5-HT1A receptors, it is more difficult to con-
clude something from the pCPA approach. Indeed, in the
latter case, pCPA would not necessarily interact negatively
with the effect of MDL 73005 (and we observed that it did
not), although there still exists a theoretical possibility that
pCPA also mimics the effects of MDL 73005 (which was not
the case). Nevertheless, the low levels of 5-HT after pCPA
treatment are in favour of an action involving the antagonist
property of MDL 73005, as one may consider that the
competition ratio between the endogenous neurotransmitter
and the exogenous drug was displaced in favour of the latter
by pCPA treatment. Therefore, the fact that MDL 73005 still
produced beneficial effects after pCPA does not exclude that
it could have acted at postsynaptic 5-HT1A receptors. Alter-
natively, as MDL 73005 exhibits properties of a D2 dopa-
minergic antagonist (Gobert et al., 1995), the effects found
after pCPA treatment might be the result of an action at D2
dopaminergic receptors. It is noteworthy that, in the second
working memory session that was run after pCPA treatment,
MDL 73005 was found to significantly reduce the distances
in rats treated with the high dose of scopolamine, an
observation that could be interpreted as reflecting an
enhancement of the effects of MDL 73005 in 5-HT-depleted
rats. Such a view requires some qualification as the treatment
with pCPA potentiated the deleterious effects of scopola-
mine, a result which is in line with previous findings (Harder
et al., 1996; Beiko et al., 1997). Thus, the pCPA-induced
potentiation of the effects of scopolamine might have created
an experimental condition where MDL 73005-induced
effects may have been more easily detectable.
Concerning catecholaminergic markers, it is remarkable
that (1) pCPA treatment has increased the concentration of
DA in the striatum (see CTRL vs. CTRL + pCPA); and (2)
the groups treated with scopolamine HBr (and pCPA)
exhibited levels of DA that were lower than in the other
groups. Similar results were found for HVA in the occipital
cortex. As such changes were not observed in rats treated
with scopolamine MBr, they are probably a consequence of
a central action of the anti-muscarinic drug. So far, we do
not know how to account for these changes, but it is
possible that repeated blockade of muscarinic receptors
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has altered the catecholaminergic tone by direct or indirect
mechanisms. It is known that systemic treatment with
scopolamine, which has no effect by itself on cortical
dopamine release, suppresses the veratine-evoked release
of DA in the frontal cortex (Liu and Kato, 1996), as well as
that induced in the striatum by treatment with clozapine
(Meltzer et al., 1994). Bymaster et al. (1993) have observed
that acute treatment (systemic) with scopolamine decreased
the level of DOPAC in the striatum, an observation con-
firming another report by Rivest and Marsden (1992).
Similar findings were obtained in the hippocampus and
the frontal cortex (Memo et al., 1988). Finally, in humans,
systemic administration of scopolamine decreases the stria-
tal binding of a D2-dopamine receptor antagonist, an obser-
vation indicative of an increased dopamine release in
response to muscarinic blockade (Dewey et al., 1993).
These few examples do not provide any clear explanation
to account for our present observations, but they are at least
in line with the idea that muscarinic blockade may interact
with the catecholaminergic tone in some brain regions.
Also, in MSCO rats, some catecholaminergic markers
were found to be higher, always significantly in comparison
to rats treated with scopolamine HBr, than in other groups.
This was the case for DA and HVA in the occipital cortex;
NA in the frontoparietal cortex; DOPAC, HVA, and NA in
the dorsal hippocampus; NA in the ventral hippocampus;
and DA in the striatum. It is very difficult to account for
these changes in the brain as scopolamine MBr is consid-
ered to exert essentially peripheral effects. It is clear that
further studies are necessary to replicate these observations
and, subsequently, to understand the involved mechanisms.
Scopolamine-induced hyperlocomotion was due to the
central action of the drug as it was not observed with
scopolamine MBr. Such results have been extensively
described in the literature (e.g., Sipos et al., 1999). Inter-
estingly, whereas it had no significant effect by itself, the
pCPA-induced 5-HT depletion enhanced the hyperlocomo-
tor effects of scopolamine. This result is in line with a
putative inhibitory role of the serotonergic system on
locomotor activity (Fibiger and Campbell, 1971). More-
over, along the same line, while ineffective by itself at the
dose used, MDL 73005 also potentiated the hyperlocomotor
effects of the high dose of scopolamine. If one considers
that the level of locomotor activity may be related to the
dopaminergic tonus, particularly in the striatum (e.g., Staton
and Solomon, 1984; Kuczenski and Segal, 1989), two
hypotheses can be proposed to account for these observa-
tions. First, although the literature is very controversial as
concerns the role of 5-HT1A receptors in the control of
striatal DA metabolism, a few studies suggest that there
may exist a 5-HT1A receptor-mediated inhibition of synth-
esis of striatal DA (e.g., Johnson et al., 1993, 1996).
Therefore, the 5-HT1A antagonist properties of MDL
73005 may have contributed to elevate striatal DA activity
in an amount sufficient to further increase locomotor
activity under the influence of muscarinic blockade. Sec-
ond, MDL 73005 has been shown to have potential
antagonist properties at D2 dopaminergic autoreceptors, an
action that is also marked by an increased striatal DA tone
(Gobert et al., 1995). This D2 antagonist property of MDL
73005 might have been all the more perceptible in scopo-
lamine-treated rats, as their decreased striatal DA concen-
trations might have accounted for an increased sensitisation
of a D2 autoreceptor-mediated inhibition of DA release.
This needs to be demonstrated. Nevertheless, each of these
effects was insufficient to alter the locomotor activity per
se, as increased locomotion was observed only in the rats
given scopolamine at the highest dose. Because the litera-
ture is very controversial as to the role of 5-HT in the
regulation of locomotor activity, it is difficult to give a
clear-cut interpretation of these results. For instance, it
appears that a 5-HT1A agonist (i.e., 8-OH-DPAT) injected
systemically induces hyperactivity (e.g., Wilkinson et al.,
1994) and potentiates the effects of scopolamine on loco-
motor activity (own unpublished observations). In the
present study, the scopolamine-induced hyperactivity was
potentiated by MDL 73005, as well as by the pCPA-
induced inhibition of 5-HT synthesis. Further studies are
required to address this question more accurately.
Our results show that scopolamine increases the swim
speed in the water maze and the locomotor activity in the
rats’ home cages. Therefore, one might consider that the
deleterious effects of scopolamine on memory performances
in the water maze could be the consequence of a sensor-
imotor bias, rather than a genuine effect upon cognition.
Also, as a consequence of the former, it might be that the
beneficial effects of MDL 73005 could be due to an action
of the compound on the sensorimotor impact of scopola-
mine. This hypothesis seems unlikely for at least two
reasons. First, the effects of scopolamine and MDL 73005
were always observed on distances, in a lesser degree on
latencies or time (in the probe trial); in the water maze,
distance is generally considered to be poorly sensitive to
sensorimotor alterations (Lindner et al., 1998). Second,
whereas MDL 73005 did not attenuate the scopolamine-
induced increase of the swim speed in the water maze or the
locomotor activity in the home cage, it actually improved
the spatial memory performances in the rats treated with the
low dose of scopolamine.
An important point to mention is the way MDL 73005
improved performances of the rats treated with the low dose
of scopolamine in our ‘‘working memory’’ protocol. Indeed,
the control rats exhibited a common pattern of learning in a
working memory test, with an important decrease of escape
distances and latencies between Trials 1 and 2. In contrast,
the rats treated with scopolamine presented a weaker
decrease of their escape distances and latencies over the
four trials, especially during the second session. The
MDL + SCO1 rats exhibited better overall performances,
but there was no amelioration from the first to the second
trial. This result suggests that the improvement of the
performances of these rats was less a matter of spatial
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allocentric working memory than a matter of change in
spatial orientation strategy. As mentioned in the Materials
and Methods, the performances of the rats in our ‘‘working
memory’’ protocol may involve two spatial memory com-
ponents, i.e., spatial allocentric orientation and egocentric
navigation relying upon nonspatial strategies to search for
the platform (route learning). Therefore, the better perfor-
mances of MDL + SCO1 rats could reflect a compensation
of the scopolamine-induced deficit of allocentric spatial
orientation by an improvement of egocentric navigation,
enabling rats to search more efficiently for the platform.
Such a shift in the spatial navigation strategy might reflect
an action of MDL 73005 on the striatum. Indeed, this
structure is involved in egocentric spatial navigation in the
water maze (e.g., Whishaw et al., 1987; McDonald and
White, 1994; Devan et al., 1996). MDL 73005 may have
acted through its 5-HT1A properties, since 5-HT1A com-
pounds may modulate the striatal dopaminergic activity
(Nissbrandt et al., 1992; Kreiss and Lucki, 1994; Johnson
et al., 1993, 1996; Santiago et al., 1998). Alternatively,
MDL 73005 may have acted through its dopaminergic D2
antagonist properties (Gobert et al., 1995; see also discus-
sion of locomotor effects), since intrastriatal administration
of sulpiride, a D2 antagonist, has been found not only to
improve memory processes (Setlaw and McGaugh, 2000)
but also to modify the strategy that rats display to find the
platform in the Morris water maze (Setlow and McGaugh,
1999). Nevertheless, such a hypothesis would need in-depth
analysis with further experiments designed at discriminating
(1) allocentric orientation vs. egocentric navigation and (2)
hippocampus vs. striatum involvement.
5. Conclusion
Our study has shown that MDL 73005 is able to improve
performances in two versions of a Morris water maze in rats
treated with a low dose of scopolamine. As these effects
were still present following 5-HT depletion induced by
pCPA treatment, it is likely that they were not due to an
action of MDL 73005 at only presynaptic 5-HT1A auto-
receptors, but rather at postsynaptic ones, or even at other
receptors such as D2 dopaminergic ones. Our results also
confirm the important role that central interactions between
cholinergic and other neurotransmitter systems, such as the
serotonergic and the dopaminergic ones, play in the regula-
tion or modulation of spatial navigation processes. As it was
given systemically in a paradigm of general cholinergic
dysfunction, MDL 73005 and similar compounds might be
one of the noncholinergic tools used for treating moderate
cognitive dysfunctions related to alterations of central cho-
linergic neurotransmission. As such, it might be of interest
as regards the treatment of cognitive alterations found in
early Alzheimer’s disease, particularly because MDL 73005
seems to work when delivered by a way more appropriate
for clinical use than intracerebral injections or other types of
invasive approaches. Further studies should be undertaken
in order (1) to investigate dose–response relationships in
models of muscarinic blockade (2 mg/kg MDL 73005 being
effective on the deficits produced by 0.25 mg/kg, but not 0.5
mg/kg scopolamine); (2) to assess whether MDL 73005 or
compounds with similar properties have a therapeutic
potential also in paradigms of selective cholinergic lesions
(e.g., with 192 IgG saporin) or in aged rodents showing
cognitive dysfunctions; and (3) to investigate the effects of
D2 receptors ligands using behavioral approaches identical
to the ones used in the present experiment.
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